The Walt Disney Company

Business

Union Pacific Revives $85 Billion Norfolk Southern Bid, Aims to Forge First Transcontinental Railroad

Union Pacific is preparing a revised application for its proposed $85 billion merger with Norfolk Southern after regulators rejected the initial filing over competition and information concerns. The deal, which would create the first coast-to-coast freight railroad in the U.S., faces intense scrutiny over its potential impact on shipping costs, labor, and market competition.

Feb 2, 2026

Business

Sony's Slump: Is the Tech Giant Undervalued After Recent Market Pressure?

Sony Group's shares have faced significant headwinds, declining over 15% in the past month. As the stock hovers around ¥3,397, analysts are divided on whether this represents a buying opportunity or a sign of deeper challenges in its gaming and sensor divisions.

Feb 2, 2026

Business

Palantir's Q4 Earnings: High Stakes for the AI Giant Amid Market Skepticism

Palantir Technologies prepares to report Q4 2025 earnings after the bell, with Wall Street eyeing $1.33 billion in revenue and $0.23 EPS. The stock's recent 17.5% slump underscores investor anxiety over its premium valuation and the sustainability of its explosive commercial growth.

Feb 2, 2026

Business

SEC Overhauls PCAOB Leadership, Appoints Demetrios Logothetis as New Chair

The U.S. Securities and Exchange Commission has ushered in a new era for the accounting watchdog, naming a fresh chair and three board members tasked with refocusing the PCAOB on its core mission of investor protection.

Feb 2, 2026

Business

Netflix's Ad Engine Fires Up: Why the Recent Stock Dip Could Be a Buying Opportunity

Despite a post-earnings sell-off, Netflix's burgeoning advertising business is laying the groundwork for sustained profit growth, presenting a potential value entry for long-term investors.

Feb 2, 2026

Business

Beyond the EV Race: Why Ferrari's Luxury Play Could Be a Decade-Long Winner

While investors flock to mass-market and electric vehicle stocks, Ferrari's unique strategy of cultivating scarcity and brand prestige has delivered enviable margins and pricing power. With shares well off their highs, analysts debate if now is the time to buy into this iconic automaker for the long haul.

Feb 2, 2026

Business

Cal-Maine Foods Weathers Price Normalization, Bets on Specialty Eggs with Strategic Acquisition

Stephens lowers price target on Cal-Maine Foods (CALM) citing near-term oversupply pressures, but the egg producer's long-term strategy remains focused on expanding its cage-free capacity through acquisition.

Feb 2, 2026

Business

Barclays Bullish on 4D Molecular Therapeutics, Sees M&A and Pricing Trends as Key Catalysts

Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.

Feb 2, 2026

Business

UiPath: A Beaten-Down Leader in the Next Wave of AI Poised for a Turnaround

Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.

Feb 2, 2026

Business

CytomX Therapeutics Gains Analyst Favor Ahead of Key Colorectal Cancer Data Release

Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.

Feb 2, 2026

Business

Intellia Therapeutics Sees Analyst Price Target Surge After FDA Lifts Clinical Hold on Key Gene Therapy Trial

Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.

Feb 2, 2026

Business

Janux Therapeutics Downgraded as Key Drug Data Gaps Raise Platform Concerns

Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.

Feb 2, 2026

Business

ExxonMobil Posts Record 2025 Results, Cementing Its Dominance in the Oil Sector

The energy giant reported industry-leading earnings and cash flow, driven by record production and deep cost cuts, while returning billions to shareholders and outlining an ambitious growth plan through 2030.

Feb 2, 2026

Business

Stifel Boosts Nurix Therapeutics Price Target to $35, Citing 2026 as Pivotal Year for Key Drug Candidate

Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.

Feb 2, 2026

Business

William Blair Touts Rambus as a Leading Force in the Booming DRAM Market

Investment firm William Blair has initiated coverage on Rambus Inc. with an 'Outperform' rating, highlighting the chip designer's dominant market share in interface circuits and its strategic positioning to capitalize on surging demand from AI data centers and server DRAM upgrades.

Feb 2, 2026

Business

NETSTREIT's Rally Raises Valuation Questions: Is the REIT Still a Buy?

NETSTREIT Corp. (NYSE: NTST) has delivered impressive shareholder returns over the past year, significantly outpacing its longer-term performance. As the stock hovers near $19, investors and analysts are debating whether its current price fully reflects the fundamentals of this necessity-based retail REIT or if momentum has gotten ahead of value.

Feb 2, 2026

Business

Allegion's 30% Surge: Is the Door Still Open for Investors?

Allegion's stock has climbed over 30% in the past year, raising questions about its current valuation. A deep dive into the numbers reveals a mixed picture, with key metrics pointing in opposite directions.

Feb 2, 2026

Business

Conagra Brands: A Value Play After the Sell-Off?

Shares of the packaged food giant have slumped over the past year, raising questions about whether the stock is a bargain or a value trap. A deep dive into valuation metrics suggests significant upside potential.

Feb 2, 2026

Business

Nvidia's AI Dominance and the $3 Trillion Data Center Boom: Why Analysts See Room to Run

As the AI infrastructure race accelerates, Nvidia's relentless innovation cycle and commanding market position point to sustained growth, with data center spending projected to reach trillions annually by 2030.

Feb 2, 2026

Business

EQB's Five-Year Surge: How a 117% Total Return Outpaced the TSX

Shares of Canadian challenger bank EQB have delivered stellar long-term gains, significantly outperforming the broader market. While recent momentum has cooled, the stock's journey offers insights into the power of dividends and shifting market sentiment.

Feb 2, 2026